Search results for: 'part ad provider it'

06 May 2016  |  Asia Pacific  |  Market Research

Global Generic Pharmaceuticals Market, Forecast to 2020

Market Participants Target High Value-added Branded Generics and Biosimilars Segments

Infographics

×

The key objectives of this research service are to gain an in-depth knowledge of the major markets and therapeutic areas and organizations presenting significant growth opportunities for generics, to understand the impact of regulation on the market, and to outline the industry consolidation trends that will continue shaping the future of generics....

21 Mar 2025  |  Global  |  Market Research

Pharmaceutical Clinical Contract Peripheral Services, Global, 2025–2030

The CRO Industry is Witnessing Transformational Growth Due to Industry Convergence and an Increasing Reliance on the Functional Service Provider (FSP) Model

Infographics

×

As trial volumes normalize after the COVID-19 pandemic, pharma and biopharma companies are re-focusing on their drug development pipelines. As a result, the market has been creating an increasing number of clinical trial outsourcing opportunities for CROs, with these service providers also refining their processes to ensure better clinical trial tu...

The global pharmaceutical industry strives to build an inclusive partner ecosystem that integrates technology, data, and regulatory standardization-enabled innovation into clinical trial delivery. This transformation aims to reduce the burden on investigators and sites while improving the efficiency and accuracy of adverse event (AE) tracking. Driv...

19 Sep 2018  |  North America  |  Market Research

Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, Forecast to 2022

Investments in Single Use/Disposable Technologies to Capitalize on Growth Opportunities in High-value Low-volume Biologics

Infographics

×

Key Issues Addressed

The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as growing cancer incidence, market needs are shifting from traditional small molecules to large molecules. This study presents an overview of the global b...

20 Nov 2017  |  North America  |  Market Research

Global Biologics Market—Companies-to-Action

Biopharma Companies are Increasingly Collaborating with CDMOs, CROs, and Digital and Medical Equipment Companies for Biologics Discovery and Development

Infographics

×

This study on the "Global Biologics Market: Companies-to-Action" presents an overview of the global biologics landscape with an emphasis on the top 10 leading bio-pharma companies in the market. The study highlights the shifting focus and investments of bio-pharma companies towards biologics discovery and development, which is attributed to the gro...

Over the last 3-5 years, growing cost pressure on healthcare and pharmaceutical companies and a significant shift towards outcome based healthcare approach have resulted in companies increasingly adopting real world data and evidence solutions to optimize their operation and cost using analytics. Earlier, applications of RWE were largely limited to...

Viral vectors are a critical part of gene therapies and genetic medicines, which are the cornerstone of precision medicines to cure rare diseases, cancers, and genetic disorders. Traditional bioprocessing, however, is tedious, less flexible, batch-based, and heavily manual; as a result, manufacturing processes involve high costs, scalability issues...

Scope of the report The research report includes the following segments: Product scope: Pharmaceutical Products Geographic scope: Ethiopia End-user scope: Pharmaceutical manufacturers, Pharmaceutical distributors, Healthcare providers, Contract Manufacturing Organisations (CMO) Revenue analysis and forecasts, drivers and restraints, business opp...

This study focuses on emerging pharmacological and non-pharmacological strategies in the treatment of obesity, as well as evolving new paradigms for the future. It describes the contribution of incretin-based therapies, particularly GLP-1 receptor agonists and their multi-agonist counterparts, which provide robust effects on weight loss and metabol...